[Omalizumab in severe asthma--case report].

Abstract	We describe the case of 31-year-old woman whose severe asthma was not properly controlled with best available therapy according to GINA (2002). Following administration of anti-IgE monoclonal antibody she experienced significant improvement in her asthma control
Authors	Agnieszka Gawlewicz-Mroczka, Ewa Nizankowska-Mogilnicka
Journal	Polskie Archiwum Medycyny Wewnetrznej (Pol Arch Med Wewn) Vol. 116 Issue 2 Pg. 766-70 (Aug 2006) Poland
Vernacular Title	Omalizumab w ciezkiej astmie--opis przypadku.
PMID	17424922 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References	Anti-Asthmatic Agents Antibodies, Anti-Idiotypic Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Omalizumab
Topics	Adult Anti-Asthmatic Agents (therapeutic use) Antibodies, Anti-Idiotypic Antibodies, Monoclonal (therapeutic use) Antibodies, Monoclonal, Humanized Asthma (complications, drug therapy) Female Humans Omalizumab Quality of Life Rhinitis, Allergic, Perennial (complications) Severity of Illness Index Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!